Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nemaura Medical, Inc. (NMRD : NSDQ)
 
 • Company Description   
Nemaura Medical Inc. is a medical technology company. It engages in developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R), BEAT(TM) diabetes, and proBEAT(TM). SugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor. Nemaura Medical Inc. is based in New York, United States.

Number of Employees: 25

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.56 Daily Weekly Monthly
20 Day Moving Average: 8,380 shares
Shares Outstanding: 24.10 (millions)
Market Capitalization: $61.70 (millions)
Beta: 0.15
52 Week High: $17.40
52 Week Low: $2.15
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.44% -21.66%
12 Week -35.84% -29.47%
Year To Date -43.86% -31.67%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
57 WEST 57TH STREET
-
Manhattan,NY 10019
USA
ph: 646-416-8000
fax: -
brets@coreir.com http://www.nemauramedical.com
 
 • General Corporate Information   
Officers
Dewan Fazlul Hoque Chowdhury - President; Chief Executive Officer
Justin Mclarney - Chief Financial Officer
Bashir Timol - Director
Timothy Johnson - Director
Salim Natha - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 640442208
SIC: 3841
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 07/05/22
Share - Related Items
Shares Outstanding: 24.10
Most Recent Split Date: 12.00 (0.10:1)
Beta: 0.15
Market Capitalization: $61.70 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.15 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 58.27
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -150.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -228.43
09/30/21 - -134.32
ROA
03/31/22 - -
12/31/21 - -38.28
09/30/21 - -34.67
Current Ratio
03/31/22 - -
12/31/21 - 1.55
09/30/21 - 1.73
Quick Ratio
03/31/22 - -
12/31/21 - 1.47
09/30/21 - 1.66
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -6,921.74
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 0.04
09/30/21 - 0.19
Inventory Turnover
03/31/22 - -
12/31/21 - 0.16
09/30/21 - 0.00
Debt-to-Equity
03/31/22 - -
12/31/21 - 8.51
09/30/21 - 2.01
Debt-to-Capital
03/31/22 - -
12/31/21 - 89.48
09/30/21 - 66.83
 

Powered by Zacks Investment Research ©